The monkeys were given the drug, ZMapp, three to five days after they were infected with the virus and when most were showing symptoms. That is several days later than any other experimental Ebola treatment tested so far.
The development of a medication to treat illness from Ebola will be accelerated under a contract...
Zogenix today announced new post-hoc analysis data showing that the indicated 12-hour dose of...
Years before Burger King sized up a Canadian headquarters in a hunt for lower taxes, Republican...
Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing ResourcesSeptember 2, 2014 2:39 pm | Comments
Particle Sciences, a CDMO for drug eluting devices, has added to its investment in development and manufacturing capabilities with the addition of a new 18mm extruder. The company now has over 6000ft2 of operating cleanroom and cGMP warehouse space including ISO5 (sterile) and two dedicated highly potent suites.
Actavis plc today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' New Drug Application (NDA) for eluxadoline, an investigational drug for the treatment of diarrhea and abdominal pain in men and women with diarrhea predominant Irritable Bowel Syndrome (IBS-D).
EMD Serono announced today that Drew Young has joined the company as Senior Vice President, Neurology and Immunology. In this capacity, he will be responsible for leading the strategic direction of the U.S. Neurology and Immunology franchise, including future products.
Regeneca Worldwide a division of VivaCeuticals, Inc. Las Vegas, NV is expanding the voluntary nationwide recall of its RegeneSlim appetite control dietary supplement to include lot #823230415, lot #EX0616r 15813, Lot # EX0616R15814 and Lot #11414re5516 because FDA analysis confirmed the presence of DMAA.
British, Hungarian and Austrian police were involved in the sweep that culminated Monday in eight arrests, including the suspected head of the scam in Vienna, police said.
Wako Chemicals' Cape Charles facility extracts the naturally pale blue blood of horseshoe crabs and processes it to yield a protein used in the medical industry to test instruments, implants and pharmaceuticals.
Foreign companies in China feel increasingly targeted for unfair enforcement of anti-monopoly and other laws and might cut investment if conditions fail to improve, a U.S. business group said Tuesday.
Pfizer and Protalix BioTherapeutics announced that the FDA approved ELELYSO™ for injection for pediatric patients. ELELYSO is therefore now indicated for long-term enzyme replacement therapy (ERT) for adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease.
DPx Holdings B.V., privately owned by JLL Partners and Royal DSM, has reached a definitive agreement to acquire all shares of Gallus BioPharmaceuticals, LLC, a contract manufacturing company specializing in biologics and current portfolio company of Ridgemont Equity Partners.
The facility was established in 1989, expanded in 2003-2006 and acquired by Olympus Biotech in 2011. It has been used primarily for mammalian cell manufacturing until production was phased out earlier this year.
The new facility, which will be the group's second-largest pharmaceutical manufacturing facility worldwide, will focus on the bulk production and packaging of Glucophage®, Concor® and Euthyrox®, Merck Serono's leading brands for the treatment of diabetes, cardiovascular diseases and thyroid disorders, respectively.
The Ebola outbreak in West Africa eventually could exceed 20,000 cases, more than six times as many as are now known, the World Health Organization said Thursday. A new plan by the U.N. health agency to stop Ebola also assumes that the actual number of cases in many hard-hit areas may be two to four times higher than currently reported. If that's accurate, it suggests there could be up to 12,000 cases already.
The National Institutes of Health announced Thursday that it is launching the safety trial on a vaccine developed by the agency's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline. It will test 20 healthy adult volunteers to see if the virus is safe and triggers an adequate response in their immune systems.
Vantictumab is being studied in combination with standard-of-care chemotherapy in three Phase 1b clinical trials in patients with advanced non-small cell lung cancer (NSCLC), advanced HER2-negative breast cancer and advanced pancreatic cancer.
IBM today announced significant advances in Watson's cognitive computing capabilities that are enabling researchers to accelerate the pace of scientific breakthroughs by discovering previously unknown connections in Big Data.